Latest News

Administration expands OUD medication access while defunding SAMHSA and restricting harm reduction.

Ukraine's integrated addiction care model outperforms U.S. fragmented approach despite war devastation and resource constraints.

Opioid settlement funds risk misallocation; MAT gaps for minors and drug court issues identified.

DEA signals openness to telemedicine prescribing of controlled substances, expanding MAT access.

Opioid settlement funds allocation overview: oversight and community impact considerations.

DEA proposed rules restrict telemedicine prescribing, harming rural patients and transgender individuals.

Overdose Awareness Day calls for holistic interventions addressing SUD as a health issue, not criminal one.

Stigma drives opposition to harm reduction programs like safe consumption sites despite strong evidence.

CANN roundtable examines COVID-19 impacts on public health advocacy, Medicaid expansion, and HIV programs.

DOJ clarifies ADA protections for people with opioid use disorder against discrimination.

Medicaid sobriety restrictions on HCV treatment contradict harm reduction and elimination goals.

MAT Act removes X-waiver requirements, expanding buprenorphine access especially in rural communities.

NIH issues RFAs for Harm Reduction Network; Biden agenda targets decriminalization and safe consumption.

CANN reflects on 2021 advocacy spanning 340B drug pricing, HIV, hepatitis C, and substance use disorder policy.

31,000 Veterans with HIV face unique barriers including comorbidities and HCV rates 3x the general population.

Study explores social-spatial networks and HIV/HCV diagnosis rates among homeless and injection drug users.

CANN roundtable discusses pandemic's impacts on HIV, HCV, STI, and SUD programs and funding weaknesses.

Stagnant CMS reimbursement rates since 2016 threaten addiction treatment provider closures and service access.

Restrictive Medicaid policies limit HCV treatment access through fibrosis restrictions and sobriety requirements.

UNAIDS report highlights HIV-HCV coinfection rates among people who inject drugs globally and in the US.